The Bcl-2 inhibitor Venetoclax and the BTK inhibitor Ibrutinib represent the main target agents used in CLL therapy able to provide durable responses in a single drug regimen. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.